Literature DB >> 10404157

Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes.

J Wagner1, P Akerud, D S Castro, P C Holm, J M Canals, E Y Snyder, T Perlmann, E Arenas.   

Abstract

The implementation of neural stem cell lines as a source material for brain tissue transplants is currently limited by the ability to induce specific neurochemical phenotypes in these cells. Here, we show that coordinated induction of a ventral mesencephalic dopaminergic phenotype in an immortalized multipotent neural stem cell line can be achieved in vitro. This process requires both the overexpression of the nuclear receptor Nurr1 and factors derived from local type 1 astrocytes. Over 80% of cells obtained by this method demonstrate a phenotype indistinguishable from that of endogenous dopaminergic neurons. Moreover, this procedure yields an unlimited number of cells that can engraft in vivo and that may constitute a useful source material for neuronal replacement in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10404157     DOI: 10.1038/10862

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  64 in total

Review 1.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease?

Authors:  Curt R Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

3.  Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons.

Authors:  Sangmi Chung; Kai-C Sonntag; Therese Andersson; Lars M Bjorklund; Jae-Joon Park; Dong-Wook Kim; Un Jung Kang; Ole Isacson; Kwang-Soo Kim
Journal:  Eur J Neurosci       Date:  2002-11       Impact factor: 3.386

4.  Exclusion of the Nurr1 gene in autosomal recessive Parkinson's disease.

Authors:  Nina Rawal; Magali Periquet; Alexandra Dürr; Giuseppe de Michele; Vincenzo Bonifati; Helio A Teive; Salmo Raskin; Joao Guimaraes; Yves Agid; Alexis Brice
Journal:  J Neurol       Date:  2002-08       Impact factor: 4.849

5.  Dopaminergic differentiation of the Nurr1-expressing immortalized mesencephalic cell line CSM14.1 in vitro.

Authors:  Stefan Jean-Pierre Haas; Andreas Wree
Journal:  J Anat       Date:  2002-07       Impact factor: 2.610

6.  Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a.

Authors:  Gonçalo Castelo-Branco; Joseph Wagner; Francisco J Rodriguez; Julianna Kele; Kyle Sousa; Nina Rawal; Hilda Amalia Pasolli; Elaine Fuchs; Jan Kitajewski; Ernest Arenas
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-13       Impact factor: 11.205

7.  Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation.

Authors:  Kai-Christian Sonntag; Rabi Simantov; Kwang-Soo Kim; Ole Isacson
Journal:  Eur J Neurosci       Date:  2004-03       Impact factor: 3.386

8.  Proceedings: cell therapies for Parkinson's disease from discovery to clinic.

Authors:  Rosa Canet-Aviles; Geoffrey P Lomax; Ellen G Feigal; Catherine Priest
Journal:  Stem Cells Transl Med       Date:  2014-08-22       Impact factor: 6.940

9.  Factors influencing the differentiation of dopaminergic traits in transplanted neural stem cells.

Authors:  Ming Yang; Angela E Donaldson; Yubao Jiang; Lorraine Iacovitti
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

10.  Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.

Authors:  A Hurtado-Lorenzo; E Millan; V Gonzalez-Nicolini; D Suwelack; M G Castro; P R Lowenstein
Journal:  Mol Ther       Date:  2004-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.